NovaQuest

NovaQuest Capital Management, LLC (NovaQuest) manages product and company investments in the global healthcare industry. Its primary focus is structured finance investments in late-stage clinical and commercialized biopharmaceutical products. NovaQuest invests side-by-side with global companies in their most strategic product programs, ensuring alignment with the biopharmaceutical companies. These customized, product transactions are an alternative to standard biopharmaceutical industry deal-making and help companies maximize the value of their product portfolios. In addition, NovaQuest invests in select private equity and other company securities, with a consistent focus on late-stage clinical and commercialized products. The NovaQuest team has worked together for over 12 years, investing over $1 billion into the global healthcare industry. The team began pursuing its strategy in 2000 as an investment group within Quintiles Transnational Holdings Inc. (Quintiles). Today, NovaQuest Capital Management is an independent firm managing global investment capital. It is backed by investors whose relationships with NovaQuest date back to the group’s inception. NovaQuest is meeting the evolving needs of global healthcare companies and its investors with a consistent strategy, developed over multiple years and transactions, that draws on a customized mix of investment and return elements and securities.
BA

Brian Axe

MD

MB

Michael Bologna

Partner

JB

John Bradley

Founding Partner, COO

Vern Davenport

Partner

AD

Abby Decker

Senior Associate

AD

Anthony DiNoto

VP

JE

Jeff Edwards

Partner

DE

Dylan Erdle

Principal

TH

Tsuyoshi Harada

Principal

Robert Hester

CFO

PJ

Patrick Jordan

Partner

Stephen Lesser

VP

CM

Chris Mauney

Senior Associate

GP

Guy Petrelli

Partner

JP

Jarett Poll

VP

DR

Devin Rosenthal

Senior Associate

CS

Christina Smith

VP

MS

Michael Sorensen

Partner

JT

Jonathan Tunnicliffe

Founding Partner, CIO

RW

Ryan Wooten

Principal

Ronald (Ron) Wooten

Founder, Managing Partner

DW

Dave Working

Senior Associate

29 past transactions

Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.

Artisan Pharma

Series C in 2010
Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Dermavant Sciences Ltd.

Private Equity Round in 2021
Dermavant Sciences is a biotechnology company focused on dermatology.

Mileutis

Venture Round in 2020
Mileutis LTD, a biopharmaceutical company, engages in the discovery, development, and commercialization of biologically sourced therapies for animal health and humans. It offers Imilac, an intramammary solution for administration at the beginning of the dry period, and the management of mastitis and increased production, as well as management, treatment, and prevention of bovine mastitis; and Milac for the treatment of intramammary infection during the lactation period. The company was founded in 2004 and is based in Ness Ziona, Israel.
Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

Protemix

Series A in 2007
Protemix is a biopharmaceutical company that discovers, develops, and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes, and other metabolic disorders. The company was founded in 1999 and is based in Auckland, New Zealand with an additional office in San Diego, California.
Myovant Sciences is to deliver innovative women's health and prostate cancer solutions by efficiently advancing new medicines to market.

Mesoblast Limited

Post in 2018
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes, and kidney disease, orthopedic spine conditions, and cardiovascular disorders. Mesoblast was founded in 2004 and is headquartered in Melbourne, Victoria.
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

Nevakar

Private Equity Round in 2019
Nevakar is a specialty pharmaceutical company, focused on developing innovative products in injectable and ophthalmic space.Their goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently [FDA] approved molecules, through intensive R&D and clinical efforts.Nevakar’s business model is supported by state of the art R&D infrastructure, located in NJ Center of Excellence, and a well experienced management and leadership team.
Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.
Applied LifeSciences & Systems is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. ALS-S is developing a solution that revolutionizes current vaccination methods. Our technology will detect, target, and deliver vaccines to each and every chick, ensuring effective vaccination. This one-of-a-kind accuracy and consistency in the vaccination process boosts the natural immune response to diseases, improves overall flock health, and provides for a cleaner, healthier chick.

Argenta

Private Equity Round in 2021
Argenta is a contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health.

Hansa Biopharma

Grant in 2022
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer using its proprietary enzyme technology platform. The company’s lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company also has licensing agreement with Axis-Shield Diagnostics Limited for Heparin Binding Protein (HBP)-assay, a method that predicts severe sepsis in emergency clinics. Hansa Biopharma AB (publ) is headquartered in Lund, Sweden.

InformedDNA

Venture Round in 2019
InformedDNA optimizes genetics-related healthcare spending and patient care by improving access to clinical and scientific genomics expertise. We are the nation’s largest independent provider network of genetics specialists enabled by a comprehensive evidence-based knowledge library for genetic tests and hereditary conditions We employ the largest full-time staff of independent, objective genetics specialists in the nation. Our high-touch, technologically-advanced approach sets us apart — and sets our customers apart. We are a partner to health plans, an advisor to health systems and providers, and an advocate for patients. Direct access to our experts empowers you to provide personalized, cutting-edge care while optimizing healthcare spending. Working with InformedDNA means connecting directly with our team and genetics resources. We’re true partners. At the core of our services, we’re committed to patients getting the right tests that lead to better care. Everyone benefits from informed decisions.

Sirion Therapeutics

Series A in 2006
Sirion Therapeutics is a Tampa, FL-based company dedicated to the development and commercialization of innovative ophthalmic products.

Pro-ficiency

Acquisition in 2021
Pro-ficiency is a leading provider of tech-enabled training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including a turn-key offering of customized, virtual training simulations, training, and compliance monitoring tools, and real-time data & predictive analytics.

Arvelle Therapeutics

Series A in 2019
Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.

Artisan Pharma

Series A in 2006
Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Clinical Ink

Private Equity Round in 2018
Clinical Ink, Inc. provides eSource solutions for the clinical trials industry. It offers SureSource, an electronic source solution that allows users to record comments, explanations, and validated source data on protocol-specific eSource documents, as well as captures the data required by the protocol. The company also provides an electronic source record (ESR) for clinical trials that provides cleaner data. In addition, it offers hosting services. Clinical Ink was founded in 2006 and is based in Winston-Salem, North Carolina.

CutisPharma

Acquisition in 2018
Azurity Pharmaceuticals is a developer of drug products and technologies to address the needs of patients. Its drug products such as antimicrobial, mouthwashes, and testosterone enable pharmacists to prepare drugs for those populations who are in need of a better alternative to traditionally-compounded medications.

Ambit Biosciences

Series D in 2011
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

BioCritica

Private Equity Round in 2011
BioCritica is a biotechnology company focused on meeting the critical care needs of patients and clinicians in the hospital market. In addition to Xigris for the treatment of severe sepsis, BioCritica is developing a pipeline of other products. Their mission is to develop and commercialize products that make a dramatic improvement in people's lives.

PreCision Dermatology

Debt Financing in 2013
PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.

CoreRx, Inc.

Acquisition in 2021
CoreRx™ is a contract pharmaceutical development organization that helps get products into the clinic faster, providing a complete spectrum of cGMP solutions for pharmaceutical dosage form development. Our wide range of support services, extensive instrumentation and rigorous quality systems provide timely results communicated in a clear, efficient and consistent manner.

Ambit Biosciences

Series D in 2007
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Roivant Sciences

Private Equity Round in 2018
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.

Arvelle Therapeutics

Series A in 2020
Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.